Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis...
Personalized cancer medicine is defined as medical care based on the
particular biological characteristics of the disease process in individual
patients. By using genomics and proteomics, individuals can
be classified into subpopulations based on their susceptibility to a particular
disease or response to a specific treatment. They may then be given preventive
or therapeutic interventions that will be most effective given their
Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Bench-to-bedside review: The value of cardiac biomarkers in the intensive care patient...
Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: the Value of Serum Biomarkers (Bc1, Bc2, Bc3) in the Diagnosis of Early Breast Cancer...
Lean thinking is not a manufacturing tactic or a cost-reduction program, but a management strategy
that is applicable to all organizations because it has to do with improving processes. All organizations
— including health care organizations — are composed of a series of processes, or sets of actions
intended to create value for those who use or depend on them (customers/patients).
Current investment management practice typically assumes that
the OE portfolio is deﬁned by the fund manager’s investment “style.”
Roughly, style refers to a subset of the investment universe in which a
manager is constrained to operate, such as small capitalization stocks
versus large stocks, or “value” versus “growth” ﬁrms. The style con-
straint may be a self-declared specialization, or it may be imposed
on the manager by the ﬁrm.
EDRN is a leader in defining and using criteria for the validation of
biomarkers—an essential condition for scientific progress. While myriad
proteins and genes have been linked with a variety of cancers, acceptable
biomarkers must be: reliable and repeatable in testing; highly sensitive
and specific; quantitative; readily obtained by non-invasive methods; part
of the causal pathway for disease; capable of being modulated by the che-
mopreventive agent; and have high predictive value for clinical disease.
Alzheimer’s Disease (AD) is an incurable, degenerative, and terminal disease with few
therapeutic options . It is a complex disease influenced by a range of genetic,
environmental, and other factors . Recently, Jack et al. demonstrated the value
of shared data in AD biomarker research. A New York Times article on the role of
data sharing, in the advancement of AD research, quotes John Trojanowski at the Uni-
versity of Pennsylvania Medical School: “It’s not science the way most of us have prac-
ticed it in our careers.
The current global epidemic of pulmonary tuberculosis
has highlighted the need for new screening
tests that are rapid and accurate. The social burden
of pulmonary tuberculosis has increased because
many patients are also infected with human
immunodeficiency virus (HIV), and the rates of
multidrug-resistant tuberculosis are increasing.1
However, screening technology has not changed
greatly during the past several decades. Many highburden
countries depend upon sputum smears and
chest radiographs, supplemented by cultures when
The objective of this current chapter is to review the techniques whose potential to noninvasively
determine Breslow index has been studied. Basic and technical principles of each
technique will be mentioned as well as their accuracy in the determination of a factor whose
importance in the clinical management of melanoma is so important as previously
demonstrated. Currently Breslow index is measured by the anatomo-pathologist after
incisional or excisional biopsy of the suspected lesion. So why non invasive determination of
Breslow index would be of utmost clinical value?...
In practice, signatures that predict toxicity or efficacy can be identified afterwards. For example,
therapies targeting the Epidermal Growth Factor Receptor have been first approved before it was
demonstrated that mutations in KRAS cancer gene were associated to failures of the relevant
therapies in metastatic colorectal carcinoma. This example shows that well-designed
retrospective analysis of data from prospective randomized controlled trials can bring forward
effective treatments to biomarker defined subgroups of patients in a timely manner.
Recent advances in clinical proteomics have propelled us into an exciting period of discovery of
new cancer biomarkers, although the available proteomic technologies have their limitations. The
principles of proteomic technology require stringent guidelines for the collection of clinical material,
the application of analytical techniques, and for our interpretation of the data.
In this review, we present an overview of the serum tumor markers in current use.